ArticleBMC pulmonary medicine2025
Risk factors for pneumonitis after the combination treatment of immune checkpoint inhibitors and thoracic radiotherapy.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Delta radiomics for predicting early radiation-induced lung injury after thoracic radiotherapy: a retrospective paired-CT study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.ESMO gastrointestinal oncology · 2026Article
- Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: A systematic review and meta-analysis.Therapeutic advances in medical oncology · 2026Article
- Adapting federated radiomics models for radiation pneumonitis prediction in patients receiving thoracic radiotherapy with immunotherapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe combination of immune checkpoint inhibitors (ICIs) and thoracic radiotherapy (TRT) has played a significant role in the improvement of tumor therapy, but the increased incidence of pneumonitis has greatly limited its application. To identify potential intervention targets, we analyzed risk factors for pneumonitis after combination therapy with ICIs and TRT.
methodsOverall, 335 patients who received TRT and ICI therapy concurrently or sequentially were included in our study. Pneumonitis was assessed and the related factors were analyzed.
resultsAfter combined TRT and ICI therapy, among the 335 patients, 219 (65.4%) patients had no pneumonitis or Grade 1 pneumonitis, 77 (23.0%) patients had Grade 2 pneumonitis, and 39 (11.6%) patients had Grade 3 or above pneumonitis. The incidence of Grade 2 or above pneumonitis was significantly related to the patients' age at diagnosis, sex, time interval and ipsilateral or bilateral lung dose‒volume parameters.
conclusionWe first showed that older, male patients are more likely to suffer from pneumonitis of Grade 2 and above. We also found that, numerically, patients who received ICIs before radiotherapy (RT) were more likely to have pneumonitis than those who received RT before ICIs. Moreover, a longer interval between treatments, lower mean lung dose (MLD) and smaller ipsilateral or bilateral lung dose‒volume parameters are correlated with a lower incidence of pneumonitis of Grade 2 or above.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.